|
|
Factsheet as on March 28, 2024 |
Factsheet as on March 28, 2024
Structure
Open Ended
Fund Category
Thematic/Sectoral
Fund Manager
Jay Kothari, Chirag Dagli
Exit Load
Within 1 Month - 0.5%
Fund Size
Rs 2352 crs
Launch Date
November 30, 2018
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.However, there can be no assurance that the investment objective of the scheme will be realized.
Market Cap Allocation
Scheme Performance
| 1 Year | 2 Years | 3 Years | 5 Years | |
| Scheme (%) | 57.76 | 23.07 | 20.57 | 26.10 |
| Nifty 500 (%) | 42.39 | 17.45 | 18.52 | 16.08 |
Top 10 Holdings
| Company Name | % of Assets |
| Sun Pharmaceuticals Ind Ltd. | 14.0 |
| IPCA Laboratories Ltd. | 8.4 |
| Suven Pharmaceuticals Ltd. | 8.3 |
| Cipla Ltd. | 8.2 |
| Lupin Ltd. | 7.5 |
| Alembic Pharmaceuticals Ltd. | 5.9 |
| Apollo Hospitals Enterprise Ltd. | 5.0 |
| Globus Medical Inc | 4.2 |
| Concord Biotech Ltd. | 4.0 |
| Zydus Lifesciences Ltd. | 3.5 |
Year On Year Performance (Scheme V/S Nifty 500)
Ratios:
| Standard Deviation | 14.89 |
| Beta | 0.74 |
| Information Ratio | -0.32 |
| Sharpe Ratio | 0.13 |
Top 10 Sectoral Holdings (%)
SIP Returns
Source: MFI Explorer, Bloomberg.
Please refer to the disclaimer and glossaries
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390
Kotak Mahindra Bank Limited, AMFI Registered Mutual Fund Distributor, ARN 1390